High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.

abstract：:Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

journal_title：Seminars in hematology

authors： Chai SJ,Macik BG

更新日期：2002-07-01 00:00:00

abstract：:In early studies, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to reduce the depth and duration of granulocytopenia in the settings of cancer chemotherapy and autologous bone marrow transplantation. In patients with myelodysplastic syndrome or aplastic anemia. GM-CSF has p...

journal_title：Seminars in hematology

authors： Gutterman J,Vadhan-Raj S,Logothetis C,Anaissle E,Estey E,Talpaz M,Kurzrock R

更新日期：1990-07-01 00:00:00

abstract：:Stem cell transplantation is a recognized treatment for many hematologic malignancies. Human leukocyte antigen (HLA) testing is a key assessment in the evaluation of potential recipients and selection of the appropriate stem cell donor. Over the past several years, technological advances have moved HLA testing from a ...

journal_title：Seminars in hematology

authors： Bray RA

更新日期：2001-04-01 00:00:00

abstract：:Although often overlooked, the life of the patient with severe hemophilia is characterized by both intermittent and chronic pain. Bleeds into joints and muscles cause extensive pressure on sensory nerves and, following recurrent bleeds, joint destruction, and synovial reaction is accompanied by constant pains that are...

journal_title：Seminars in hematology

authors： Ingerslev J,Hvid I

更新日期：2006-01-01 00:00:00

abstract：:Anemia is frequent and significantly adds to the morbidity of cancer patients, and has been associated with decreased quality of life (QOL). Three open-label community-based studies of epoetin alfa in cancer-related anemia (two using three-times-weekly dosing and one using once-weekly dosing) in more than 7,000 patien...

journal_title：Seminars in hematology

authors： Soignet S

更新日期：2000-10-01 00:00:00

abstract：:The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM ...

journal_title：Seminars in hematology

authors： Coleman M,Armitage JO,Gaynor M,McDermott D,Weisenburger DD,Adler K,Beshevkin M,Silver RT,Reisman AM,Pasmantier MW

更新日期：1988-04-01 00:00:00

abstract：:Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

journal_title：Seminars in hematology

authors： Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

更新日期：2010-07-01 00:00:00

abstract：:Thrombosis is a common and potentially serious complication of immune-mediated heparin-induced thrombocytopenia (HIT). Discontinuation of heparin is a simple and important maneuver in patients with suspected HIT. Unfortunately, thrombosis often occurs even in those patients in whom heparin was discontinued because of ...

journal_title：Seminars in hematology

authors： Warkentin TE

更新日期：1998-10-01 00:00:00

abstract：:Hemangiomas and lymphangiomas are two main types of angiomatous disease that occur most commonly in infancy and childhood. Most hemangiomas resolve spontaneously, but some endanger vital structures such as the lung, as in pulmonary hemangiomatosis, a rare and universally fatal disease. Occasionally, hemangiomatous les...

journal_title：Seminars in hematology

authors： White CW

更新日期：1990-07-01 00:00:00

abstract：:Antibody-mediated rejection (AMR) is a major risk factor for graft loss following kidney transplantation. Traditional anti-humoral therapies provide suboptimal therapy and they do not deplete plasma cells, which are the source of antibody production. Proteasome inhibitors (PI) have been shown to deplete both transform...

journal_title：Seminars in hematology

authors： Sadaka B,Alloway RR,Shields AR,Schmidt NM,Woodle ES

更新日期：2012-07-01 00:00:00

abstract：:By definition, myeloproliferative disorders (MPDs) are caused by an acquired somatic mutation of a hematopoietic progenitor/stem cell and have sporadic occurrence. However, well-documented families exist with first-degree relatives acquiring one or several MPDs. It is reasonable to assume that the germ-line mutation(s...

journal_title：Seminars in hematology

authors： Skoda R,Prchal JT

更新日期：2005-10-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal proliferation of myeloid progenitors leading to erythrocytosis, thrombocytosis, or leukocytosis, and risk of hemorrhagic and thrombotic events, as well as ...

journal_title：Seminars in hematology

authors： Ferreira Cristina S,Polo B,Lacerda JF

更新日期：2018-10-01 00:00:00

abstract：:Two membrane proteins express the antigens that comprise the Kell blood group system. A single antigen, Kx, is carried on XK, a 440-amino acid protein that spans the membrane 10 times, and more than 20 antigens reside on Kell, a 93-kd, type II glycoprotein. XK and Kell are linked, close to the membrane surface, by a s...

journal_title：Seminars in hematology

authors： Lee S,Russo D,Redman CM

更新日期：2000-04-01 00:00:00

abstract：:Imatinib (Gleevec) (formerly STI571) competitively targets the adenosine 5-triphosphate (ATP) binding site of the kinase domain of ABL and was recently approved for the treatment of chronic myeloid leukemia (CML). Point mutations occurring in the kinase domain of BCR-ABL have been identified as a cause of imatinib res...

journal_title：Seminars in hematology

authors： Roche-Lestienne C,Preudhomme C

更新日期：2003-04-01 00:00:00

abstract：:Anemia of chronic disease (ACD) or inflammation may be secondary to infections, autoimmune disorders, chronic renal failure, or malignancies. It is characterized by an immune activation with an increase in inflammatory cytokines and resultant increase in hepcidin levels. In addition, inappropriate erythropoietin level...

journal_title：Seminars in hematology

authors： Gangat N,Wolanskyj AP

更新日期：2013-07-01 00:00:00

abstract：:Endogenous thrombopoietin (TPO) stimulates platelet production in nonhuman primates by inducing dose-dependent megakaryocyte development from early marrow hematopoietic progenitors and subsequent proliferation and endoreduplication. In nonhuman primates, recombinant human TPO, nonpegylated or pegylated rHu megakaryocy...

journal_title：Seminars in hematology

authors： Harker LA

更新日期：1998-07-01 00:00:00

abstract：:Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma. We summarized our experience with thalidomide alone, and then in combination with dexamethasone, for groups of patients with myeloma resistant or relapsing despite standard treatments. Criteria of r...

journal_title：Seminars in hematology

authors： Alexanian R,Weber D,Anagnostopoulos A,Delasalle K,Wang M,Rankin K

更新日期：2003-10-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a complex and heterogeneous disease with distinct age-associated genomic and epigenomic alterations. A large number of somatic karyotypic and molecular alterations have been identified in AML to date; however, very few predict outcome or identify potential therapeutic targets. Here we d...

journal_title：Seminars in hematology

authors： Schuback HL,Arceci RJ,Meshinchi S

更新日期：2013-10-01 00:00:00

abstract：:Idiopathic thrombocytopenic purpura (ITP) is an illness of primary acquired thrombocytopenia occurring in the absence of marrow failure. Splenectomy was first used as a treatment for ITP in 1913. However, with the realization that opsonin (critical for the optimal killing of invasive micro-organisms by white blood cel...

journal_title：Seminars in hematology

authors： Bell WR Jr

更新日期：2000-01-01 00:00:00

abstract：:Activation products of the terminal complement cascade potently affect granulocyte function, inducing, for example, their migration toward (chemotaxis), and adherence to (opsonization), microbes, and stimulating their production of microbicidal oxygen radicals such as superoxide anion, and the like. We present studies...

journal_title：Seminars in hematology

authors： Craddock PR,Hammerschmidt DE,Moldow CF,Yamada O,Jacob HS

更新日期：1979-04-01 00:00:00

abstract：:Shwachman-Diamond syndrome (SDS) is an autosomal recessive marrow failure syndrome associated with exocrine pancreatic insufficiency and leukemia predisposition. Bone marrow failure typically manifests with neutropenia, but anemia, thrombocytopenia, or aplastic anemia may also develop. Additional organ systems, such a...

journal_title：Seminars in hematology

authors： Shimamura A

更新日期：2006-07-01 00:00:00

abstract：:The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

journal_title：Seminars in hematology

authors： Richardson P

更新日期：2005-10-01 00:00:00

abstract：:Primary immune thrombocytopenic purpura (ITP) remains a diagnosis of exclusion both from nonimmune causes of thrombocytopenia and immune thrombocytopenia that develops in the context of other disorders (secondary immune thrombocytopenia). The pathobiology, natural history, and response to therapy of the diverse causes...

journal_title：Seminars in hematology

authors： Cines DB,Liebman H,Stasi R

更新日期：2009-01-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by malignant expansion of bone marrow stem cells. Currently, the only unequivocally curative treatment for CML is allogeneic stem cell transplant. Unfortunately, a large proportion of CML patients are ineligible for such treatment and alternative...

journal_title：Seminars in hematology

authors： Barnes DJ,Melo JV

更新日期：2003-01-01 00:00:00

abstract：:In previous studies, treatment with epoetin alfa facilitated preoperative donation of autologous blood (AB). However, some patients may not be able to donate sufficient AB to meet their surgical blood requirements when the time to surgery is short. In this multicenter, double-blind, placebo-controlled study, the abili...

journal_title：Seminars in hematology

authors： Tryba M

更新日期：1996-04-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesyl...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：2001-07-01 00:00:00

abstract：:Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the ...

journal_title：Seminars in hematology

authors： La Rosée P,Deininger MW

更新日期：2010-10-01 00:00:00

abstract：:Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the inten...

journal_title：Seminars in hematology

authors： Bonadonna G,Santoro A,Viviani S,Valagussa P

更新日期：1988-04-01 00:00:00

abstract：:Imatinib (Gleevec) (formerly STI571) is an orally bioavailable rationally developed inhibitor of the tyrosine kinases Bcr-Abl, Kit, and platelet-derived growth factor receptor (PDGFR). In 4 years of clinical development, more than 12,000 patients have been treated in the clinical development program. Imatinib was firs...

journal_title：Seminars in hematology

authors： Capdeville R,Silberman S

更新日期：2003-04-01 00:00:00

abstract：:Familial thrombosis has long been considered as an autosomal dominant trait, caused by a dominant gene defect with a reduced penetrance for the disease. Recently, this view has changed and today familial thrombophilia is considered as a complex genetic disorder caused by the segregation of two or more gene defects (kn...

journal_title：Seminars in hematology

authors： Koeleman BP,Reitsma PH,Bertina RM

更新日期：1997-07-01 00:00:00